07:35 AM EST, 02/23/2026 (MT Newswires) -- C4 Therapeutics ( CCCC ) said Monday it has dosed the first patient under the phase 2 trial evaluating cemsidomide, in combination with dexamethasone, for the treatment of relapsed/refractory multiple myeloma.

The trial targets to enroll 100 patients and its primary endpoint is overall response rate. The company expects to complete patient enrollment for the trial in Q1 2027.

C4 Therapeutic also said it expects to start a phase 1b trial of cemsidomide in combination with elranatamab in q2 and complete further analysis of the concluded phase 1 trial of cemsidomide in combination with dexamethasone in mid-2026.